Abstract: The present invention relates to parenteral compositions comprising methylene blue, water and one or more pH regulating agents. The present invention also relates to processes for preparing such compositions.

Abstract: The present invention relates to a composition comprising high purity pyrrole derivative and method for preparation thereof. The present invention particularly relates to compositions comprising Saroglitazar magnesium having purity of 99.0% or more, and one or more of an aldehyde compound of Formula (II), diketo oxirane compound of Formula (III), hydroxy methyl compound of Formula (IV) or dimer compound of Formula (V), relative to saroglitazar magnesium, each present in an amount of about 0.15% or less, respectively, by weight, when measured by area percentage of HPLC.

Abstract: The present invention relates to pharmaceutical compositions containing the formula (I) for the prevention, delay of progression, or treatment of a disease or condition from hepatocellular carcinoma. The present invention further provides the composition of formula (I) useful in the prevention and treatment of hepatocellular carcinoma.

Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Abstract: The present invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and optionally one or more controlled release substances. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of inflammatory bowel disease.

Abstract: The present invention provides a stable pharmaceutical composition comprising apomorphine and one or more pharmaceutically acceptable carriers in an injectable device. The present invention also provides a process for preparing the stable pharmaceutical composition.

Abstract: Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.

Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1? activity is implicated.

Abstract: The invention relates to process for the preparation of isoxazoline-substituted benzamide compound and intermediates thereof. The invention also relates to process for the preparation of Fluralaner and intermediates thereof.

Abstract: The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof. It also relates to controlling nitrosamine impurity, 7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP) in the composition, wherein the NTTP does not exceed the FDA's established acceptable intake limit of 0.37 ppm per day at release and during shelf-life.

Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Abstract: The present invention relates to modified release pharmaceutical compositions of riociguat or a pharmaceutically acceptable salt thereof. In particular, the compositions of the invention are stable, possess formulation characteristics and also provide extended therapeutically effective plasma levels over twenty four hour time period. The invention also relates to processes of preparing such compositions.